Logo image of NBIX

NEUROCRINE BIOSCIENCES INC (NBIX) Stock Fundamental Analysis

NASDAQ:NBIX - US64125C1099 - Common Stock

136.69 USD
-5.23 (-3.69%)
Last: 9/3/2025, 3:51:04 PM
Fundamental Rating

7

Taking everything into account, NBIX scores 7 out of 10 in our fundamental rating. NBIX was compared to 542 industry peers in the Biotechnology industry. NBIX scores excellent points on both the profitability and health parts. This is a solid base for a good stock. NBIX is growing strongly while it is still valued neutral. This is a good combination! These ratings could make NBIX a good candidate for growth and quality investing.


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

In the past year NBIX was profitable.
NBIX had a positive operating cash flow in the past year.
In the past 5 years NBIX has always been profitable.
NBIX had a positive operating cash flow in each of the past 5 years.
NBIX Yearly Net Income VS EBIT VS OCF VS FCFNBIX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

1.2 Ratios

NBIX has a Return On Assets of 8.95%. This is amongst the best in the industry. NBIX outperforms 93.54% of its industry peers.
Looking at the Return On Equity, with a value of 12.93%, NBIX belongs to the top of the industry, outperforming 93.73% of the companies in the same industry.
NBIX has a better Return On Invested Capital (10.85%) than 94.46% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for NBIX is below the industry average of 15.95%.
Industry RankSector Rank
ROA 8.95%
ROE 12.93%
ROIC 10.85%
ROA(3y)7.79%
ROA(5y)10.24%
ROE(3y)11.14%
ROE(5y)15.22%
ROIC(3y)11.4%
ROIC(5y)11.57%
NBIX Yearly ROA, ROE, ROICNBIX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40

1.3 Margins

NBIX's Profit Margin of 13.88% is amongst the best of the industry. NBIX outperforms 93.17% of its industry peers.
In the last couple of years the Profit Margin of NBIX has grown nicely.
NBIX has a Operating Margin of 19.89%. This is amongst the best in the industry. NBIX outperforms 94.46% of its industry peers.
In the last couple of years the Operating Margin of NBIX has declined.
NBIX has a Gross Margin of 98.49%. This is amongst the best in the industry. NBIX outperforms 97.42% of its industry peers.
In the last couple of years the Gross Margin of NBIX has remained more or less at the same level.
Industry RankSector Rank
OM 19.89%
PM (TTM) 13.88%
GM 98.49%
OM growth 3Y10.53%
OM growth 5Y-2.95%
PM growth 3Y22.39%
PM growth 5Y25.28%
GM growth 3Y-0.06%
GM growth 5Y-0.1%
NBIX Yearly Profit, Operating, Gross MarginsNBIX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

7

2. Health

2.1 Basic Checks

NBIX has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
NBIX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for NBIX has been increased compared to 5 years ago.
NBIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NBIX Yearly Shares OutstandingNBIX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
NBIX Yearly Total Debt VS Total AssetsNBIX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

An Altman-Z score of 8.53 indicates that NBIX is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 8.53, NBIX belongs to the top of the industry, outperforming 83.76% of the companies in the same industry.
There is no outstanding debt for NBIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 8.53
ROIC/WACC1.1
WACC9.84%
NBIX Yearly LT Debt VS Equity VS FCFNBIX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B 2B 2.5B

2.3 Liquidity

A Current Ratio of 3.20 indicates that NBIX has no problem at all paying its short term obligations.
The Current ratio of NBIX (3.20) is worse than 61.99% of its industry peers.
NBIX has a Quick Ratio of 3.10. This indicates that NBIX is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 3.10, NBIX is not doing good in the industry: 60.33% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 3.2
Quick Ratio 3.1
NBIX Yearly Current Assets VS Current LiabilitesNBIX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

8

3. Growth

3.1 Past

NBIX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.11%.
Measured over the past years, NBIX shows a very strong growth in Earnings Per Share. The EPS has been growing by 58.39% on average per year.
NBIX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 18.42%.
The Revenue has been growing by 24.48% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)2.11%
EPS 3Y35.58%
EPS 5Y58.39%
EPS Q2Q%68.25%
Revenue 1Y (TTM)18.42%
Revenue growth 3Y27.61%
Revenue growth 5Y24.48%
Sales Q2Q%16.49%

3.2 Future

NBIX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 36.54% yearly.
The Revenue is expected to grow by 12.21% on average over the next years. This is quite good.
EPS Next Y37.34%
EPS Next 2Y41.39%
EPS Next 3Y37.25%
EPS Next 5Y36.54%
Revenue Next Year18.52%
Revenue Next 2Y16.56%
Revenue Next 3Y14.98%
Revenue Next 5Y12.21%

3.3 Evolution

Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
NBIX Yearly Revenue VS EstimatesNBIX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B 5B
NBIX Yearly EPS VS EstimatesNBIX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 10 15

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 40.44, NBIX can be considered very expensive at the moment.
Based on the Price/Earnings ratio, NBIX is valued cheaper than 91.88% of the companies in the same industry.
NBIX's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.90.
NBIX is valuated rather expensively with a Price/Forward Earnings ratio of 20.78.
92.25% of the companies in the same industry are more expensive than NBIX, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.52, NBIX is valued at the same level.
Industry RankSector Rank
PE 40.44
Fwd PE 20.78
NBIX Price Earnings VS Forward Price EarningsNBIX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

92.99% of the companies in the same industry are more expensive than NBIX, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, NBIX is valued cheaper than 94.10% of the companies in the same industry.
Industry RankSector Rank
P/FCF 25.64
EV/EBITDA 23.48
NBIX Per share dataNBIX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20 25

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The excellent profitability rating of NBIX may justify a higher PE ratio.
A more expensive valuation may be justified as NBIX's earnings are expected to grow with 37.25% in the coming years.
PEG (NY)1.08
PEG (5Y)0.69
EPS Next 2Y41.39%
EPS Next 3Y37.25%

More info and screens

0

5. Dividend

5.1 Amount

NBIX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEUROCRINE BIOSCIENCES INC

NASDAQ:NBIX (9/3/2025, 3:51:04 PM)

136.69

-5.23 (-3.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-30 2025-07-30/amc
Earnings (Next)10-28 2025-10-28/bmo
Inst Owners96.9%
Inst Owner Change-0.2%
Ins Owners1.02%
Ins Owner Change0.74%
Market Cap13.56B
Analysts83.53
Price Target169.76 (24.19%)
Short Float %4.09%
Short Ratio4.49
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-39.31%
Min EPS beat(2)-85.62%
Max EPS beat(2)7%
EPS beat(4)1
Avg EPS beat(4)-33.29%
Min EPS beat(4)-85.62%
Max EPS beat(4)7%
EPS beat(8)2
Avg EPS beat(8)-28.41%
EPS beat(12)3
Avg EPS beat(12)-78.74%
EPS beat(16)4
Avg EPS beat(16)-77.91%
Revenue beat(2)1
Avg Revenue beat(2)1.57%
Min Revenue beat(2)-0.14%
Max Revenue beat(2)3.28%
Revenue beat(4)2
Avg Revenue beat(4)0.63%
Min Revenue beat(4)-2.16%
Max Revenue beat(4)3.28%
Revenue beat(8)4
Avg Revenue beat(8)1.07%
Revenue beat(12)6
Avg Revenue beat(12)0.68%
Revenue beat(16)8
Avg Revenue beat(16)0.67%
PT rev (1m)3.83%
PT rev (3m)6.86%
EPS NQ rev (1m)9.67%
EPS NQ rev (3m)33.87%
EPS NY rev (1m)13.36%
EPS NY rev (3m)12.69%
Revenue NQ rev (1m)1.69%
Revenue NQ rev (3m)7.52%
Revenue NY rev (1m)3.91%
Revenue NY rev (3m)4.03%
Valuation
Industry RankSector Rank
PE 40.44
Fwd PE 20.78
P/S 5.4
P/FCF 25.64
P/OCF 23.9
P/B 5.03
P/tB 5.1
EV/EBITDA 23.48
EPS(TTM)3.38
EY2.47%
EPS(NY)6.58
Fwd EY4.81%
FCF(TTM)5.33
FCFY3.9%
OCF(TTM)5.72
OCFY4.18%
SpS25.31
BVpS27.17
TBVpS26.79
PEG (NY)1.08
PEG (5Y)0.69
Profitability
Industry RankSector Rank
ROA 8.95%
ROE 12.93%
ROCE 14.93%
ROIC 10.85%
ROICexc 15.33%
ROICexgc 15.57%
OM 19.89%
PM (TTM) 13.88%
GM 98.49%
FCFM 21.06%
ROA(3y)7.79%
ROA(5y)10.24%
ROE(3y)11.14%
ROE(5y)15.22%
ROIC(3y)11.4%
ROIC(5y)11.57%
ROICexc(3y)30.35%
ROICexc(5y)27.29%
ROICexgc(3y)31.58%
ROICexgc(5y)28.03%
ROCE(3y)15.68%
ROCE(5y)15.92%
ROICexcg growth 3Y35.59%
ROICexcg growth 5Y-0.37%
ROICexc growth 3Y34.3%
ROICexc growth 5Y-0.94%
OM growth 3Y10.53%
OM growth 5Y-2.95%
PM growth 3Y22.39%
PM growth 5Y25.28%
GM growth 3Y-0.06%
GM growth 5Y-0.1%
F-Score7
Asset Turnover0.65
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 135.44%
Cap/Sales 1.54%
Interest Coverage 250
Cash Conversion 107.53%
Profit Quality 151.79%
Current Ratio 3.2
Quick Ratio 3.1
Altman-Z 8.53
F-Score7
WACC9.84%
ROIC/WACC1.1
Cap/Depr(3y)126.53%
Cap/Depr(5y)144.2%
Cap/Sales(3y)1.41%
Cap/Sales(5y)1.47%
Profit Quality(3y)172.36%
Profit Quality(5y)166.13%
High Growth Momentum
Growth
EPS 1Y (TTM)2.11%
EPS 3Y35.58%
EPS 5Y58.39%
EPS Q2Q%68.25%
EPS Next Y37.34%
EPS Next 2Y41.39%
EPS Next 3Y37.25%
EPS Next 5Y36.54%
Revenue 1Y (TTM)18.42%
Revenue growth 3Y27.61%
Revenue growth 5Y24.48%
Sales Q2Q%16.49%
Revenue Next Year18.52%
Revenue Next 2Y16.56%
Revenue Next 3Y14.98%
Revenue Next 5Y12.21%
EBIT growth 1Y-8.37%
EBIT growth 3Y41.04%
EBIT growth 5Y20.8%
EBIT Next Year3.69%
EBIT Next 3Y22.67%
EBIT Next 5Y19.85%
FCF growth 1Y88.28%
FCF growth 3Y33.71%
FCF growth 5Y32.31%
OCF growth 1Y91.53%
OCF growth 3Y32.41%
OCF growth 5Y31.38%